9342-8530 Québec Inc.

Equities

DGCR.F

CA2519121016

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:51:48 2022-12-20 pm EST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2016	DiagnoCure Announces Resignation of Frederic Boivin as Interim CFO, Effective March 28, 2016	CI
2016	DiagnoCure, Inc. Reports Consolidated Earnings Results for the First Quarter Ended January 31, 2016	CI

DiagnoCure Inc. Reports Consolidated Earnings Results for the Third Quarter Ended July 31, 2014

September 11, 2014 at 05:01 pm EDT

DiagnoCure Inc. reported consolidated earnings results for the third quarter ended July 31, 2014. For the quarter, the company reported total revenues of $153,424 against $189,585 a year ago. This decrease of $36,161 or 19% is mostly attributable to PCA3 royalties, reflecting a decrease in U.S. royalty revenues.

Net loss (before stock-based compensation, depreciation and amortization) was $406,853 against $351,753 a year ago. Net loss and comprehensive loss was $504,105 against $595,262 a year ago. Basic and diluted net loss per share was $0.01 against $0.01 a year ago.

Latest news about 9342-8530 Québec Inc.

DiagnoCure Announces Resignation of Frederic Boivin as Interim CFO, Effective March 28, 2016	16-03-14	CI
DiagnoCure, Inc. Reports Consolidated Earnings Results for the First Quarter Ended January 31, 2016	16-03-11	CI
Gen-Probe Incorporated completed the acquisition of assets related to PCA3 prostate cancer biomarker from DiagnoCure Inc..	16-02-16	CI
DiagnoCure Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended October 31, 2015; Reports Impairment of Intangible Asset for the Fourth Quarter Ended October 31, 2015	16-01-21	CI
Gen-Probe Incorporated entered into an asset purchase agreement to acquire all assets related to PCA3 prostate cancer biomarker from DiagnoCure Inc. for CAD 6.5 million.	15-12-22	CI
DiagnoCure Inc. Reports Earnings Results for the Third Quarter Ended July 31, 2015	15-09-11	CI
DiagnoCure Inc. Announces Earnings Results for the Six Months Ended April 30, 2015	15-06-22	CI
DiagnoCure, Inc. Reports Earnings Results for the Second Quarter Ended April 30, 2015	15-06-12	CI
DiagnoCure Inc. Announces Board Changes	15-06-12	CI
DiagnoCure, Inc. Reports Consolidated Financial Results for the First Quarter Ended January 31, 2015	15-03-06	CI
DiagnoCure Inc. Announces Earnings Results for the Fourth Quarter and Fiscal Year Ended October 31, 2014	15-01-23	CI
DiagnoCure Inc. Reports Consolidated Earnings Results for the Third Quarter Ended July 31, 2014	14-09-11	CI
DiagnoCure Inc. Announces Earnings Results for the Six Months Ended April 30, 2014	14-06-13	CI
DiagnoCure Inc. Announces Earnings Results for the Second Quarter Ended April 30, 2014	14-06-04	CI
DiagnoCure, Inc. Reports Consolidated Earnings Results for the First Quarter Ended January 31, 2014	14-03-14	CI
Transcript : DiagnoCure Inc., Q4 2013 Earnings Call, Jan 16, 2014	14-01-16
DiagnoCure, Inc. Reports Earnings Results for the Fourth Quarter 2013 and Fiscal Year Ended October 31, 2013	14-01-16	CI
DiagnoCure Inc. Announces Resignation of Chantal Miklosi as CFO Effective October 11, 2013	13-10-01	CI
Transcript : DiagnoCure Inc., Q3 2013 Earnings Call, Sep 04, 2013	13-09-04
DiagnoCure Inc. Announces Earnings Results for the Third Quarter Ended July 31, 2013	13-09-04	CI
DiagnoCure Inc. Appoints Richard Bordeleau as Senior Advisor, Effective September 1, 2013	13-08-20	CI
Transcript : DiagnoCure Inc., Q2 2013 Earnings Call, Jun 03, 2013	13-06-03
DiagnoCure Inc. Announces Earnings Results for the Second Quarter Ended April 30, 2013	13-06-03	CI
DiagnoCure Reports Data from a New Study on GCC Assay	13-06-03	CI
Declaration of Voting Results by DiagnoCure	13-04-28	CI

Chart 9342-8530 Québec Inc.

Duration

Period

More charts

Company Profile

9342-8530 Quebec Inc is a Canada-based biotechnology company. The Company specializes in the development and commercialization of products relating to the diagnosis of cancer. It intends to focus its activities on business development efforts by out-licensing, selling, or partnering with third parties with regards to its Previstage GCC and its new multimarker prostate cancer test (PCP). The Company's colorectal cancer staging test, Previstage GCC, uses the Guanylyl Cyclase C (GCC or GUCY2C) marker to stratify the risk of colon cancer recurrence by determining the stage of the disease. Previstage GCC Colorectal Cancer Staging test is a molecular test for the staging of colorectal cancer patients. The PROGENSA PCA3 assay is a molecular urine test that can be used as a predictor of biopsy outcome in men with a serum prostate specific antigen (PSA) level over 2.5 nanograms per milliliter (ng/ml).

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
9342-8530 QUÉBEC INC.	-.--%	43
IQVIA HOLDINGS INC.	+0.17%	42.86B
MODERNA, INC.	+10.92%	42.74B
LONZA GROUP AG	+44.30%	41.36B
CELLTRION, INC.	-6.20%	27.68B
ICON PUBLIC LIMITED COMPANY	+5.23%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-24.79%	18.63B
MEDPACE HOLDINGS, INC.	+26.69%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.13%	11.92B
UNITED THERAPEUTICS CORPORATION	+6.57%	11.21B

Other Biotechnology & Medical Research